Cargando…

Real-life temocillin use in Greater Paris area, effectiveness and risk factors for failure in infections caused by ESBL-producing Enterobacterales: a multicentre retrospective study

BACKGROUND: Temocillin is a β-lactam that is not hydrolysed by ESBLs OBJECTIVES: To describe the real-life use of temocillin, to assess its effectiveness in infections caused by ESBL-producing Enterobacterales, and to identify risk factors for treatment failure. METHODS: Retrospective multicentric s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dinh, Aurélien, Duran, Clara, Singh, Simrandeep, Tesmoingt, Chloé, Bouabdallah, Laura, Hamon, Antoine, Antignac, Marie, Ourghanlian, Clément, Loustalot, Marie-Caroline, Pain, Jean Baptiste, Wyplosz, Benjamin, Junot, Helga, Bleibtreu, Alexandre, Michelon, Hugues
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798080/ https://www.ncbi.nlm.nih.gov/pubmed/36601547 http://dx.doi.org/10.1093/jacamr/dlac132

Ejemplares similares

Impact of revised breakpoints on the categorization of susceptibility of Enterobacterales to temocillin
por: Farfour, Eric, et al.
Publicado: (2023)

Activity of temocillin against ESBL-, AmpC-, and/or KPC-producing Enterobacterales isolated in Poland
por: Kuch, Alicja, et al.
Publicado: (2020)

Correction to: Real-life temocillin use in Greater Paris area, effectiveness and risk factors for failure in infections caused by ESBL-producing Enterobacterales: a multicentre retrospective study
Publicado: (2023)

Rapid detection of temocillin resistance in Enterobacterales
por: Findlay, Jacqueline, et al.
Publicado: (2023)

In vitro activity of mecillinam, temocillin and nitroxoline against MDR Enterobacterales
por: Plambeck, Lars, et al.
Publicado: (2022)

Clinical outcomes of temocillin use for invasive Enterobacterales infections: a single-centre retrospective analysis
por: Heard, Katie L, et al.
Publicado: (2021)

Clinical and microbiological evaluation of temocillin for bloodstream infections with Enterobacterales: a Belgian single-centre retrospective study
por: Oosterbos, Julie, et al.
Publicado: (2022)

Budget impact analysis of temocillin insurance coverage for urinary tract infections caused by ESBL-producing pathogens in Iran
por: Seyedifar, Meysam, et al.
Publicado: (2023)

Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study
por: Bleibtreu, Alexandre, et al.
Publicado: (2021)

Detection of Multidrug-Resistant Enterobacterales—From ESBLs to Carbapenemases
por: Noster, Janina, et al.
Publicado: (2021)

CON: Testing for ESBL production is unnecessary for ceftriaxone-resistant Enterobacterales
por: Mathers, Amy J, et al.
Publicado: (2021)

Carbapenem-Resistant and ESBL-Producing Enterobacterales Emerging in Central Texas
por: Parker, Jennifer K, et al.
Publicado: (2023)

Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTARTÉ): protocol for a randomised, pragmatic trial
por: Marín-Candón, Alicia, et al.
Publicado: (2021)

2760. Fecal Microbiota Transplantation for Decolonization of Carbapenemase-Producing Enterobacterales
por: Davido, Benjamin, et al.
Publicado: (2023)

Analysis of Extended Spectrum Beta Lactamase (ESBL) Genes of Non-Invasive ESBL Enterobacterales in Southeast Austria in 2017
por: Paulitsch-Fuchs, Astrid H., et al.
Publicado: (2022)

Impact of Omicron surge in community setting in greater Paris area
por: Dinh, Aurélien, et al.
Publicado: (2022)

Should ceftriaxone-resistant Enterobacterales be tested for ESBLs? A PRO/CON debate
por: Villegas, Maria Virginia, et al.
Publicado: (2021)

ESBL Activity, MDR, and Carbapenem Resistance among Predominant Enterobacterales Isolated in 2019
por: Bandy, Altaf, et al.
Publicado: (2021)

Antibiotic Stewardship in Treatment of Osteoarticular Infections Based on Local Epidemiology and Bacterial Growth Times
por: Vidal, Pauline, et al.
Publicado: (2022)

Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales
por: Darlow, Christopher A, et al.
Publicado: (2021)

The Impact of COVID-19 Pandemic on ESBL-Producing Enterobacterales Infections: A Scoping Review
por: Mai, Ha Thi Thao, et al.
Publicado: (2023)

Continuous versus intermittent infusion of temocillin in intensive care unit patients
por: Claeysoone, K, et al.
Publicado: (2005)

Temocillin: Applications in Antimicrobial Stewardship as a Potential Carbapenem-Sparing Antibiotic
por: Lupia, Tommaso, et al.
Publicado: (2022)

Semi-quantitative cultures of throat and rectal swabs are efficient tests to predict ESBL-Enterobacterales ventilator-associated pneumonia in mechanically ventilated ESBL carriers
por: Andremont, Olivier, et al.
Publicado: (2020)

Monitoring of Non-β-Lactam Antibiotic Resistance-Associated Genes in ESBL Producing Enterobacterales Isolates
por: Shinu, Pottathil, et al.
Publicado: (2020)

Carriage of ESBL-producing Enterobacterales in wastewater treatment plant workers and surrounding residents — the AWARE Study
por: Rodríguez-Molina, Daloha, et al.
Publicado: (2021)

Correction to: Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales
por: Darlow, Christopher A, et al.
Publicado: (2022)

647. Cefepime Versus Carbapenems for the Treatment of ESBL-producing Enterobacterales among Non-blood Isolates
por: Garcia, Brandon, et al.
Publicado: (2022)

Clinical Efficacy of Temocillin Standard Dosing in Patients Treated with Outpatient Antimicrobial Therapy
por: Van den Broucke, Evelyne, et al.
Publicado: (2022)

Empirical use of temocillin in hospitalized patients: results from a retrospective audit
por: Kandil, Hala, et al.
Publicado: (2023)

Prevalence of ESBL, AmpC and Carbapenemase-Producing Enterobacterales Isolated from Raw Vegetables Retailed in Romania
por: Colosi, Ioana Alina, et al.
Publicado: (2020)

PRO: Testing for ESBL production is necessary for ceftriaxone-non-susceptible Enterobacterales: perfect should not be the enemy of progress
por: Tamma, Pranita D, et al.
Publicado: (2021)

Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales—authors’ response
por: Darlow, Christopher A, et al.
Publicado: (2022)

197. The Clinical Impact of Early Detection of ESBL-Producing Enterobacterales with PCR-Based Blood Culture Assays
por: Chang, Kai-Ming, et al.
Publicado: (2022)

Correction to: Empirical use of temocillin in hospitalized patients: results from a retrospective audit
Publicado: (2023)

Impact de la pandémie COVID-19 sur les consommations hospitalières en antibiotiques, étude monocentrique d’un ESR métropolitain
por: Junot, H., et al.
Publicado: (2020)

Occurrence, Typing, and Resistance Genes of ESBL/AmpC-Producing Enterobacterales in Fresh Vegetables Purchased in Central Israel
por: Kon, Hadas, et al.
Publicado: (2023)

Risk factors for predicting extended-spectrum β-lactamase-producing Enterobacterales (ESBLE) infections in non-urinary isolates
por: Burgoon, Rachel, et al.
Publicado: (2023)

Impact of Omicron surge in community setting in greater Paris area
por: Dinh, A., et al.
Publicado: (2022)

Hip Joint Infections Caused by Multidrug-Resistant Enterobacterales Among Patients With Spinal Cord Injury: Experience of a Reference Center in the Greater Paris Area
por: Davido, B, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rpto61p0gjibae38m5shfqkc70